Tonic clonic status epilepticus Simon Shorvon Tonic clonic status epilepticus can be defined as a condition in which prolonged or recurrent tonic clonic seizures persist for 30 minutes or more. From indirect studies, the annual incidence of tonic clonic status has been estimated to be approximately 18-28 cases per 100 000 persons (9-14 000 new cases each year in the UK, or 45-70 000 cases in the USA).'2 It is most frequent in children, the mentally handicapped, and in those with structural cerebral pathology (especially in the frontal areas). In established epilepsy, status may be precipitated by drug withdrawal, intercurrent illness or metabolic disturbance, or the progression of the underlying disease, and is more common in symptomatic than in idiopathic epilepsy. About 5% of all epileptic adult clinic patients will have at least one episode of status in the course of their epilepsy,'2 and in children the proportion is higher (10-25%).'-' Most status episodes, however, do not develop in known epileptic patients, and in such cases are almost always due to acute cerebral disturbances; common causes are cerebral infection, trauma, cerebrovascular disease, cerebral tumour, acute toxic or metabolic disturbance, febrile illness (in children). Recent studies have shown status to account for about 3-5% of admissions to neurological intensive care,4 and 0>13% of all visits to a university hospital casualty department.5 The mortality of tonic clonic status is about 5-10%, most patients dying of the underlying condition, rather than the status itself or its treatment.' 2 Permanent neurological and mental deterioration may result from status, particularly in young children, the risks of morbidity being greatly increased the longer the duration of the status episode.36 Tonic clonic status is only one of the forms of status epilepticus (see table 1), and indeed is not the most common. Nevertheless, unlike other types, it is a medical emergency. Treatment is urgent because the longer seizures continue, the worse the outcome and the more hazardous is therapy. Successful management is a balance between the conflicting requirements of controlling seizure activity as quickly as possible, and minimising physiological changes and medical complications.
Pathophysiology of tonic clonic status epilepticus
The pattern of seizures in tonic clonic status evolves over time. There is often a premonitory stage of minutes or hours, during which epileptic activity increases in frequency or severity from its habitual level. This clinical deterioration is an augury, often stereotypic, of impending status, and urgent therapy may well prevent its full development. At the onset of status, the attacks typically take the form of discrete grand mal seizures. As time passes, however, the convulsive motor activity often evolves, first to become continuous, and then clonic jerking becomes less pronounced and less severe, and finally ceases altogether. This is the stage of "subtle status epilepticus",7 by which time, the patient will be deeply unconsciousness, and the prognosis is poor. In parallel to this clinical evolution, there is also sometimes a progressive change in the EEG, 9 although how consistently such a progressive clinical and EEG pattern occurs is not known. Autonomic changes in status can be profound, and dominate the clinical picture, These include hyperpyrexia, tachycardia, cardiac arrhythmia, blood pressure changes, apnoea, sweating, hypersecretion and massive noradrenalin and adrenalin release. Other profound endocrine changes also occur.
The physiological changes in status are often divided into two phases, the transition from phase 1 to 2 occurring after about minutes of continuous seizures.2 [10] [11] [12] Whilst this is a generally useful concept, it must be 3) Intraveous lines should be set up for fluid replacement and drug administration (preferably with 0 9% sodium chloride (normal saline) rather than 5% glucose solutions). Drugs should not be mixed, and if two antiepileptic drugs are needed (for example, phenytoin and diazepam), two intravenous lines should be sited. The lines should be in large veins, as many antiepileptic drugs cause phlebitis and thrombosis at the site of infusion. Arterial lines must never be used for drug administration. 4) Emergency investigations: Blood should Diazepam192" has a time honoured place as a drug of first choice in premonitory or early stages of status. Its pharmacology and clinical effects have been extensively studied in adults, children and the newborn, and it has been shown to be highly effective in a wide range of status types. Diazepam can be given by intravenous bolus injections or by the rectal route in the premonitory stage, and has a rapid onset of action. Sufficient cerebral levels are reached within one minute of a standard intravenous injection, and rectal administration produces peak levels at about 20 minutes. The drug is rapidly redistributed, and has a relatively short duration of action after a single intravenous injection. After repeated dosing, as drug concentrations in the peripheral compartments (lipid stores) increase, this redistribution does not occur. Thus repeated bolus injections produce high peak levels which persist, carrying an attendant risk of sudden and unexpected CNS depression and cardiorespiratory collapse. Diazepam is metabolised by hepatic microsomal enzymes. Respiratory depression, hypotension and sedation are the principal side-effects. Sudden apnoea can occur, especially after repeated injections or if the injection is administered at too fast a rate.
Bolus intravenous doses of diazepam should be given in an undiluted form at a rate not exceeding 2-5 mg/minute, using the Diazemuls formulation. Diazepam may be given rectally, either in its intravenous preparation infused from a syringe via a plastic catheter, or as the ready made proprietary rectal tube preparation Stesolid, the latter is a convenient and easy method. Diazepam suppositories should not be used, as absorption is too slow. The adult bolus intravenous or rectal dose in status is 10-20 mg, and additional 10 mg doses can be given at 15 minute intervals, to a maximum of 40 mg. In children, the equivalent bolus dose is 0-2-0-3 mg/kg. A continuous infusion of benzodiazepine has also been used, but there is now little place for this mode of administration. The solution should be freshly prepared, and no drugs should be admixed.
The usual IV formulation is as an emulsion (Diazemuls) in a 1 mL ampoule containing 5mg/mL or as a solution in 2 mL ampoules containing 5 mg/mL. Stesolid is the usual rectal formulation, 2-5 mL rectal tube containing 2 mg/mL 4 mg/mL. The IV solution can also be instilled rectally.
Midazolam: Midazolam2427 has only recently been recently introduced in status, and clinical experience is limited. Unique amongst the drugs in status, it can be given by intramuscular injection, as well as by the rectal or intravenous routes. Bioavailability after intramuscular injection is about 80-100%, and peak levels are reached after about 25 minutes although there is marked individual variation. Its elimination kinetics are dependent on hepatic blood flow. The lipid solubility of the drug, and hence its cerebral action, is reduced as pH falls. Action is short-lived, and there is a strong tendency to relapse following a single bolus injection. It is cleared from the body faster than diazepam, and there is thus less tendency to accumulate. Midazolam exhibits the same toxic effects as other benzodiazepines, including sedation, hypotension and cardiorespiratory depression. Respiratory arrest may occur occasionally even after intramuscular injection so careful monitoring is imperative. Intramuscular use in premonitory status, where immediate facilities for intravenous injection are often not available, is a great advantage. This is the main current role for midazolam in status, but further experience may widen its indications.
Midazolam is usually given intramuscularly or rectally in premonitory status, at a dose of 5-10 mg (in children 0 15-0-3 mg/kg), which can be repeated once after 15 minutes or so. A 5-10 mg intravenous bolus injection can also be given (repeated to a maximum of 0-3 mg/kg in adults), and there is limited experience of an intravenous infusion. Midazolam is available in 5 mL ampoules containing 2 mg/mL or 2 mL ampoules containing 5 mg/mL.
Paraldehyde:
Paraldehyde2830 is a thoroughly old fashioned medication, but is still widely used in the treatment of status epilepticus. Its main indication is as an alternative or sequel to the administration of diazepam in the stage of premonitory or early status. It is especially useful in situations where intravenous administration is difficult, or where conventional antiepileptic drugs are contra-indicated or have proved ineffective. The drug is usually given rectally (or less often intramuscularly), and absorption by both routes is fast and complete. The onset of action is rapid and paraldehyde is effective for many hours. Seizures tend to recur less after control is achieved than with the shorter acting benzodiazepines, anaesthetic drugs or chlormethiazole. Paraldehyde has no strong tendency to accumulate, and the risks of hypotension or cardiorespiratory depression are low. Toxicity is unusual providing: the correct dose is not exceeded; the solution is freshly made; the paraldehyde is not decomposed; is diluted satisfactorily. Inappropriately diluted or decomposed paraldehyde is highly toxic by any route of administration. The intramuscular injection must be into deep (usually gluteal) muscle, well away from the sciatic nerve. In established status, paraldehyde can be given by intravenous infusion, but this is a complicated and fraught procedure, and one which is now very rarely recommended. The drug also reacts with rubber and plastic, and so if infused, must be given via glass giving sets and syringes. An injection using a plastic syringe, however, is acceptable if given rapidly after drawing the solution up.
In early status, paraldehyde can be given at a dose of 10-20 mL of 50% solution rectally or intramuscularly (children 0-07-0 35 mLikg), which can be repeated once after 15-30 minutes.
In established status in adults, it can be given by continuous infusion, as a solution of 15 mL ampoules in 500 mL of 5% dextrose freshly made up every three hours, given at a dose of 15-30 mL every three hours (that is, approximately 100-200 mg/kg/h). There is now no place for the bolus injection of undiluted paraldehyde even into a fast running drip. In neonatal status, an infusion of 200 mg/kg/h can be given for at least three hours, or an initial infusion of 200 mg/kg/h followed by 16 mg/kg/h for 12 hours.
Paraldehyde is supplied in 1OmL ampoules (approximately 10 grams) in darkened glass to prevent decomposition. For rectal or intramuscular administration, it is diluted in equal measure with 0-9% sodium chloride (normal saline) or arachis oil. For intravenous administration, it should be given as a 5% infusion in 5% dextrose, freshly made up every three hours.
Chlormethiazole: Chlormethiazole3'-34 is widely used at the stage of established status, by continuous intravenous infusion. Distribution is very rapid, and there is a large volume of distribution. A single intravenous injection has a very rapid effect, which is very short lived. Chlormethiazole is thus best given as a continuous infusion, and the dose can be titrated according to effect on a moment to moment basis, without inducing deep anaesthesia. This ability to titrate the dose is very useful, and unique amongst the drugs used in status. On longer-term therapy, however, as the drug concentrations in peripheral lipid compartments approach saturation levels, this property is lost. Sudden accumulation'may cause persistingly high blood levels, resulting in sudden cardiorespiratory collapse, cardiac arrhythmia, hypotension or deep sedation. In view of this risk, prolonged use of the drug should be avoided where possible. If a longterm infusion (> 12 hours) is judged necessary, it is wise to reduce the dose every few hours to minimise accumulation. There is a tendency for seizures to recur as chlormethiazole is weaned, and longer-term oral supplementation is sometimes required. On prolonged therapy there is a danger of fluid overload, and electrolyte supplementation may be required as the infusion fluid is electrolyte-deficient. The elimination of chlormethiazole is markedly affected by changes in hepatic blood flow and by hepatic disease. The drug is absorbed by PVC on prolonged contact. Although its pharmacokinetics are well studied, there have been no formal clinical trials of chlormethiazole in status, and published experience of its use, especially in the long-term and in children or the newborn is very limited.
In status, an initial intravenous infusion of 40-100 mL of the 0-8% solution is given (that is, 320-800 mg) at a rate of 5-15 mL/minute. The infusion is continued at a minimum dose which will control seizures (commonly 0-5-4 mL/minute, maximum 20 mL/minute in adults). When seizures are controlled (for 12 hours in a case of adult status), the rate of infusion should be slowly reduced. It is not uncommon for seizures to recur on chlormethiazole withdrawal, in which case the minimum effective dose should again be determined and continued. Sometimes, switching from the intravenous to oral form (1-3 capsules of 192 mg chlormethiazole base a day, or 1-3 500 mg tablets of chlormethiazole edisylate, or 5-15 mL of chlormethiazole edisylate syrup) is necessary as status resolves. An infusion rate of 0-01 mlikg/minute (0-08 mg/kg/minute) in children has been recommended, increasing every 2-4 hours until seizures are abolished or drowsiness intervenes. The drug is usually supplied in 500 mL bottles of a 0-8% solution of chlormethiazole edisylate (8 mg/mL) in dextrose and sodium hydroxide.
Lorazepam:
Lorazepam2" 35- 12 hours (longer than with diazepam), but repeated doses are much less effective, and the drug has no place as long-term therapy. Lorazepam has sedative effects shared by all the benzodiazepine drugs used in status, but sudden hypotension or respiratory collapse are less likely because of its relative lipid-insolubility and the lack of accumulation after single bolus injections.
Lorazepam is administered by intravenous bolus injection. As distribution is slow, the rate of injection is not critical. In adults, a bolus dose of 0-07 mg/kg (to a maximum of 4 mg) is given, and this can be repeated once after 20 minutes if no effect has been observed. In children under 10 The rate of infusion of phenytoin solution should not exceed 50 mg/minute, and it is prudent to reduce this to 20-30 mg/minute in the elderly. The adult dose is [15] [16] [17] [18] mg/Kg; usually about 1000 mg, therefore taking at least 20 minutes to administer. Regrettably, a lower dose is too often given, which results in suboptimal cerebral levels. This is a common and potentially serious mistake. Phenytoin therapy can be continued after intravenous loading by oral or further intravenous daily dosages of 5-6 mg/kg individual doses, guided by blood level measurements. For older children, the dose of phenytoin is as for adults. For the newborn a dose of 15-20 mg/kg, injected at a rate not exceeding 1 mg/kg/minute, should be given. Phenytoin is usually available as 5 mL ampoules containing phenytoin sodium 250 mg. Phenobarbitone: Phenobarbitone43-46 is a drug of choice for the treatment of established status. It is highly effective, has a rapid onset of action and prolonged anticonvulsant effects. It has stable and non-reactive physical properties, and convenient pharmacokinetics. Wide experience has been gained of its use in adults and in children, and few drugs are as well tried in the newborn. It has stronger anticonvulsant properties than most other barbiturates, and may be preferentially concentrated in metabolically active epileptic foci. As well as excellent anticonvulsant properties, it may also have cerebral-protective action. Acute tolerance to the antiepileptic effect is unusual, in contrast to the benzodiazepines, and once controlled, seizures do not tend to recur. The main disadvantages of phenobarbitone are its potential to cause sedation, respiratory depression and hypotension; although in practice these effects seem slight except at high levels or with rapidly rising levels, and its safety at even high doses is well established. The well-known chronic side-effects of phenobarbitone in long-term therapy are of no relevance in the emergency situation of status. The drug is eliminated slowly, and whilst this is of no importance on initial phenobarbitone loading, on prolonged therapy there is a danger of accumulation, and blood level monitoring is essential. In the newborn period dosing is more difficult than in adults, as the pharmacokinetics change rapidly during the first weeks and months of life. The drug has a strong tendency to auto-induction. Phenobarbitone is a stable preparation which does not easily decompose, nor is the drug absorbed by plastic. It should not be used in a solution containing other drugs (for example, phenytoin), as this may result in precipitation.
The usual recommended adult intravenous loading dose is 10 mg/Kg, given at a rate of 100 mg/minute (that is, a total of about 600 mg in six, minutes). This should be followed by daily maintenance doses of 1-4 mg/kg. The initial maximum adult dose should not exceed 1000 mg as the drug is not very lipid soluble and in obese patients, the mg/kg guide may be unreliable. In neonates, initial phenobarbitone loading doses of between 12-20 mg/kg have been recommended to produce therapeutic levels, with subsequent supplementation of 3-4 mg/kg per day, to a maximum dose of 40 mg/kg. In older children, loading dose of between 5-20 mg/kg are recommended and maintenance doses of 1-4 mg/kg, although much higher doses have been safely given. After loading, maintenance doses can be given by the oral, intravenous or intramuscular route. Phenobarbitone is usually presented in 1 mL ampoules containing 200 mg of phenobarbitone sodium. Thiopentone: Thiopentone47-50 is the compound traditionally used for barbiturate anaesthesia in status epilepticus, at least in Europe. It is an effective antiepileptic drug, and may have additional cerebral-protective effects. In the doses used in status it has anaesthetic action, and all patients require intubation and most artificial ventilation. The most troublesome sideeffect is persisting hypotension and many patients require pressor therapy. Thiopentone has saturable pharmacokinetics, and a strong tendency to accumulate. Thus if large doses are given, blood levels may remain very high for protracted periods, and days may pass before consciousness is recovered after drug administration is discontinued. Blood level monitoring, both of the thiopentone and its active metabolite pentobarbitone, is therefore essential on prolonged therapy. Other toxic effects on prolonged therapy include pancreatitis and hepatic disturbance, and thiopentone may cause acute hypersensitivity. It should be administered cautiously in the elderly, and in those with cardiac, hepatic or renal disease. Although it has been in use since the 1960s in status, formal clinical trials of its safety and effectiveness in either adults and children are few. A full range of ITU facilities are required during thiopentone infusions. Central venous pressure should be monitored, and blood pressure via an arterial line. Swan-Ganz monitoring is sometimes advisable, and EEG or cerebral function monitoring is essential if thiopentone infusions are prolonged. A concomitant dopamine infusion is frequently needed to maintain blood pressure. Thiopentone can react with polyvinyl infusion bags or giving sets. The continuous infusion should be made up in 09% sodium chloride (normal saline). The intravenous solution has a pH of 10-2-11-2, is incompatible with a large number of acidic or oxidising substances, and no drugs should be added. The aqueous solution is unstable if exposed to air.
The dose regime commonly used is as follows: thiopentone is given as a 100-250 mg bolus over 20 seconds, with further 50 mg boluses every 2-3 minutes until seizures are controlled, with intubation and artificial ventilation. The intravenous infusion is then continued at the minimum dose required to control seizure activity (burst suppression on the EEG), usually between 3-5 mg/kg/hour, and at thiopentone blood levels of about 40 mg/L. After 24 hours, the dose should be controlled by blood level monitoring. After 2-3 days or so, metabolism may be near saturation, and daily or twice daily blood level estimations should be made to ensure that levels do not rise excessively. The dose should be lowered if systolic blood pressure falls below 90 mm Hg, or if vital functions are impaired. Thiopentone should be continued for no less than 12 hours after seizure activity has ceased, and then slowly discontinued.
The usual preparation is as a 2-5 g vial with 100 mL of diluent to produce a 2-5% solution. Propofol: In recent times, there has been a vogue for the use of non-barbiturate anaesthesia in status; of the currently available compounds, propofol51-54 is probably the drug of choice. Published experience, however, is very limited of its use in status, or indeed of its longterm administration in any clinical situation. Propofol is a highly effective and nontoxic anaesthetic. Although, in experimental models, it has intrinsic anticonvulsant properties, it has caused seizures in anaesthetic practice. Propofol is extremely soluble in lipid, and has a high volume of distribution. It thus acts extremely rapidly in status. Its effects are maintained whilst the infusion is continued, and recovery following discontinuation of the drug is also very quick; in marked contrast to thiopentone. Theoretically, there is a danger of accumulation on very long-term therapy, but this has been reported in practice. Propofol administration causes profound respiratory and cerebral depression, requiring the use of assisted respiration, the full panoply of intensive care and monitoring, but only mild hypotension, and has few cardiovascular side effects. Long term administration causes marked lipaemia and may result in acidosis. It may cause involuntary movements which should not be mistaken for seizures. Although propofol has been the subject of only a few case reports, it is widely used in status, and warrants further formal study. Its safety in young children has not been established.
In status, the following regime can be used: initially a 2 mg/kg bolus dose is given, which can be repeated if seizures continue, succeeded by an infusion of 5-10 mg/kg/hour guided by EEG. The dose should be gradually reduced, and the infusion tapered 12 hours after seizure activity is halted. In the elderly, doses should be lower. It is available as 20 mL ampoules containing 10 mg/mL, as an emulsion.
Other drugs:
A wide variety of other drugs have been used in status, including clonazepam, lignocaine, pentobarbitone, etomidate, magnesium sulphate, clorazepate, corticosteroids, valproate, lamotrigine. Few of these (or indeed the firstline) drugs have received adequate formal clinical study in status, and their relative merits are largely uncertain. An exciting area of future research is the use of cerebro-protective agents, to prevent status-induced cerebral damage. A more detailed discussion of the 
